Ensysce Biosciences (ENSC) Change in Cash (2018 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Change in Cash of -$538357.0 for Q3 2025, down 117.31% year-over-year from $3.1 million in Q3 2024, and up 35.98% quarter-over-quarter from -$840916.0 in Q2 2025.
Ensysce Biosciences (ENSC) Change in Cash (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Change in Cash for 8 consecutive years, with -$538357.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Change in Cash fell 117.31% year-over-year to -$538357.0; the TTM figure through Sep 2025 stood at -$2.5 million (down 192.23% YoY), while the FY2024 annual figure was $2.4 million, up 217.51% from the prior year.
- Change in Cash advanced to -$538357.0 in Q3 2025 per ENSC's latest filing, from -$840916.0 in the prior quarter.
- Across five years, Change in Cash topped out at $7.7 million in Q2 2021 and bottomed at -$4.7 million in Q2 2022.
- Historically, Change in Cash has averaged $77842.3 across 5 years, with a median of -$538357.0 in 2025.
- Annual changes were most pronounced in 2021 — Change in Cash surged 1122.14% — and 2022, when it plunged 4095.05%.
- Ensysce Biosciences' Change in Cash stood at $5.4 million in 2021, then slumped by 125.01% to -$1.4 million in 2022, then soared by 74.86% to -$340777.0 in 2023, then slumped by 91.19% to -$651515.0 in 2024, then rose by 17.37% to -$538357.0 in 2025.
- Business Quant data shows ENSC's Change in Cash at -$538357.0 in Q3 2025, -$840916.0 in Q2 2025, and -$449586.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -538,357.00 |
| Jun 30, 2025 | -840,916.00 |
| Mar 31, 2025 | -449,586.00 |
| Dec 31, 2024 | -651,515.00 |
| Sep 30, 2024 | 3.11 Mn |
| Jun 30, 2024 | -2.36 Mn |
| Mar 31, 2024 | 2.28 Mn |
| Dec 31, 2023 | -340,777.00 |
| Sep 30, 2023 | -2.37 Mn |
| Jun 30, 2023 | 2.41 Mn |
| Mar 31, 2023 | -1.73 Mn |
| Dec 31, 2022 | -1.36 Mn |
| Sep 30, 2022 | 768,435.00 |
| Jun 30, 2022 | -4.71 Mn |
| Mar 31, 2022 | -3.82 Mn |
| Dec 31, 2021 | 5.42 Mn |
| Sep 30, 2021 | -1.17 Mn |
| Jun 30, 2021 | 7.72 Mn |
| Mar 31, 2021 | 95,713.00 |
| Dec 31, 2020 | -530,168.00 |